Artiva reports Q2 net loss $17.8M; IPO raises $179M extending cash runway through 2026

Artiva Biotherapeutics, Inc.

2024-Q2 EPS reported -$39.24 revenue$251,000

IPO in July 2024 raised $179M gross; cash $46.6M pre-IPO, runway now through 2026.
Net loss Q2 2024: $17.8M vs $11.3M YoY; R&D expense $12.3M (up 9%).
Collaboration revenue $0 vs $3.5M in Q2 2023 after Merck deal termination.
First patient dosed in autoimmune basket trial (AlloNK + rituximab); first LN patient in Phase 1/1b.
Expect initial AlloNK autoimmune data in H1 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.